Abstract This retrospective study examines the clinical outcomes and immune reconstitution dynamics in patients with severe aplastic anemia (SAA) exhibiting mixed chimerism (MC) compared with those with full donor chimerism (FDC) following HLA-matched hematopoietic stem cell transplantation (HSCT). Analysis of propensity score-matched cohorts (23 MC vs 69 FDC) revealed comparable 5-year overall survival (OS: 87.0% vs 92.8%, P = .433) but significantly inferior failure-free survival (FFS: 47.8% vs 87.0%, P .001) in patients with MC due to a higher incidence of graft failure (52.2% vs 8.7%, P .001). Longitudinal immune profiling revealed delayed recovery of myeloid and lymphoid lineages in patients with MC at 12 months post-HSCT, with pronounced deficits in adaptive immunity. Specifically, CD8+CD28+ T cell counts were consistently reduced at 1 month (median, 20 vs 41 cells/μL, P = .049), 3 months (median, 86 vs 153 cells/μL, P = .024), and 6 months (median, 109 vs 160 cells/μL, P = .001), and CD4+CD25+ T cells were diminished at 6 months (median, 11 vs 20 cells/μL, P = .006). Multivariate analysis revealed that elevated CD8+CD28+ T cell levels at 3 months (≥140 cells/μL) were an independent predictor of improved FFS (HR = 0.30, P = .035). These findings highlight MC-associated immune dysregulation, particularly impaired CD28-costimulated T cell and CD4+CD25+ T cell reconstitution, as a key mediator of graft instability. This study underscores the prognostic value of early immune monitoring and suggests therapeutic strategies that target T cell recovery to mitigate MC-related risk in patients with SAA.
Lin et al. (Mon,) studied this question.